Nucleotide Oligomerization Domain-like receptor 4 (NLR4) Gene Expression and Interleukin 1-β (IL 1-β) Level in Urine Samples Before and After Intravesical BCG Therapy For Treatment of Bladder Cancer
Bladder cancer is the 7th most commonly diagnosed cancer in males worldwide and the 11th when both genders are considered. Seventy five per cent of bladder cancer cases are non-muscle invasive bladder cancer (NMIBC). Bacillus Calmette–Gu rin (BCG) immunotherapy remains the standard intravesical agen...
Main Authors: | Ahmed Samar Abd Elmoaty Eissa, Ossama Rasslan, Lamia Fouad, Fahim Hisham Abdelmajeed, Amira Esmail Abdel-Hamid |
---|---|
Format: | Article |
Language: | Russian |
Published: |
St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
2021-01-01
|
Series: | Медицинская иммунология |
Subjects: | |
Online Access: | https://www.mimmun.ru/mimmun/article/view/2101 |
Similar Items
-
Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience
by: Vivek Sharma, et al.
Published: (2020-12-01) -
BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer
by: Sarah Lidagoster, et al.
Published: (2024-02-01) -
Secondary Haemophagocytic Lymphohistiocytosis Syndrome (HLH) After Intravesical Instillation of Bacillus Calmette-Guérin (BCG): A Case Report and Review of the Literature
by: Konstantinos Manganas, et al.
Published: (2022-10-01) -
Late-onset granulomatous prostatitis following intravesical bacille Calmette-Guerin therapy: case report
by: Octavio Castillo Cádiz, et al.
Published: (2016-06-01) -
Protective role of intravesical BCG in COVID-19 severity
by: Héctor Gallegos, et al.
Published: (2021-03-01)